Clario Reveals Updated Oncology Trial Solutions Portfolio: The Industry’s Widest Range of Endpoint Collection Technologies

Clario Oncology Trial Solutions offers a proven and comprehensive portfolio, integrating innovative trial methodologies and technologies with vast scientific and regulatory expertise, generating higher-quality evidence faster, and accelerating the success of oncology development programs.

PHILADELPHIA, PA – September 5, 2023 – Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today unveiled “Clario Oncology Trial Solutions” – the industry’s broadest range of endpoint collection technologies. This solutions portfolio is optimized to help transform lives, with a focus on efficacy, safety and quality of life, to meet the demands of modern oncology clinical development programs.

Clario Oncology Trial Solutions has been developed from an unmatched 50 years of clinical trial and regulatory experience in over 120 countries, and industry-leading scientific expertise in eCOA, Cardiac Safety, Medical Imaging, Respiratory and Precision Motion.

Clario has:

• Been involved in more than 5,000 oncology trials
• Played a pivotal role in 75% of all FDA approvals of oncology compounds since 2012
• Enrolled more than one million patients worldwide in oncology studies

Clario’s unparalleled experience has led to the development of an integrated suite of oncology endpoint technologies that can be tailored to meet a trial’s specific needs. Oncology researchers are able to partner with Clario to gather the most accurate data from trial participants with a fine-tuned and tailored approach that helps unlock evidence for a successful study.

“The potential impact of a successful oncology clinical trial on individual patient lives is immense. At Clario, we understand the urgency of bringing safe and effective treatments to market, and that is why we have focused on developing the broadest portfolio of solutions to generate the highest quality data in cancer studies,” said Todd Rudo, M.D., Chief Medical Officer of Clario. “Clario’s medical and scientific expertise is revolutionizing what’s possible, from innovative trial methodologies to novel endpoint collection technologies. We are generating the richest evidence possible to demonstrate the safety and efficacy of emerging therapies. Our oncology trial solutions ensure we deliver the regulatory-compliant data that modern trials demand.”

Dr. Rudo continued, “Additionally, Clario is fully committed to accelerating and diversifying cancer research to further extend our impact on transforming patients’ lives. We are forming strategic partnerships with groups with similar goals as part of that commitment. Earlier this year, we announced a new partnership with CancerX and the White House Cancer Moonshot. Clario will support this initiative to rapidly accelerate the pace of cancer innovation and enhance patient care.”

For more information on Clario Oncology Trial Solutions, please visit Clario.com.